You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

 

Online download statistics by month:

Online download statistics by month: June 2021 to November 2024

AbstractFullPdf
Jun 202110941093406
Jul 2021311311128
Aug 2021288288139
Sep 202118218291
Oct 2021199199123
Nov 2021151150104
Dec 202111711951
Jan 202211212086
Feb 202211011392
Mar 2022110118131
Apr 2022104105113
May 2022121127156
Jun 2022153163107
Jul 2022208214136
Aug 2022223232158
Sep 2022271282159
Oct 2022185198118
Nov 2022182182109
Dec 202215015293
Jan 2023167176135
Feb 2023228231117
Mar 2023242245167
Apr 2023138139107
May 202317517994
Jun 202315916190
Jul 2023175179107
Aug 2023218220125
Sep 202317117273
Oct 202315415583
Nov 202320120188
Dec 2023150151104
Jan 202412812987
Feb 2024183184118
Mar 2024221225183
Apr 2024152161254
May 2024161161100
Jun 2024181181102
Jul 2024249252116
Aug 2024201201130
Sep 2024215215247
Oct 2024257259132
Nov 2024256262165
Total865387875424